Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Review
Pharmacology & Pharmacy
James Isaacs, Thomas E. Stinchcombe
Summary: Approximately one-third of NSCLC patients can undergo surgical resection. Neoadjuvant and adjuvant chemotherapy have been shown to improve survival outcomes. Recent trials have explored immunotherapy and targeted therapy in early-stage patients, showing improved disease-free survival.
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medicine, General & Internal
Chenchen Zhao, Haifeng Yan, Wentai Pang, Tong Wu, Xianbin Kong, Xiaojiang Li, Honggen Liu, Linlin Zhao, Feng Liang, Yingjie Jia
Summary: This study evaluated the effectiveness and safety of lentinan combined with cisplatin thoracic injection in the treatment of lung cancer through meta-analysis of 17 clinical RCTs involving 1390 patients. The results showed statistically significant improvements in clinical efficacy, effective subgroup analysis, and quality of life with this treatment. Adverse reactions were also lower in the lentinan combined with cisplatin group compared to cisplatin alone. However, due to methodological quality issues and bias in current studies, further rigorous and well-designed RCTs are needed for verification.
Review
Oncology
Wen-Fang Tang, Hong-Yu Ye, Xuan Tang, Jian-Wei Su, Kang-Mei Xu, Wen-Zhao Zhong, Yi Liang
Summary: Chemotherapy is currently the standard adjuvant treatment for early-stage non-small cell lung cancer (NSCLC), but its effectiveness in improving 5-year survival rates is limited. Immunotherapy using immune checkpoint inhibitors (ICIs) has shown great potential in treating advanced NSCLC, and there is growing interest in its role in early-stage NSCLC. This article summarizes the rationale for adjuvant immunotherapy, ongoing clinical trials, and challenges in the field, and emphasizes the need for further research and validation of the role of adjuvant immunotherapy in early-stage NSCLC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Guanghui Huang, Wenhong Li, Min Meng, Yang Ni, Xiaoying Han, Jiao Wang, Zhigeng Zou, Tiehong Zhang, Jianjian Dai, Zhigang Wei, Xia Yang, Xin Ye
Summary: This study evaluated the preliminary outcomes of microwave ablation (MWA) + intratumoral chemotherapy (ITC) for large non-small cell lung cancer (NSCLC) and found that it is a safe and effective local treatment method that can significantly prolong local progression-free survival (LPFS).
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang
Summary: Despite advancements in diagnosis and treatment, lung cancer mortality remains high. This review provides an overview of current diagnostic methods and therapies for non-small cell lung cancer, serving as a guide for clinicians.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Ibrahim Azar, Omid Yazdanpanah, Hyejeong Jang, Adam Austin, Seongho Kim, Jie Chi, Samer Alkassis, Biplab K. Saha, Amit Chopra, Kristoffer Neu, Syed Mehdi, Hirva Mamdani
Summary: There is no significant difference in survival outcomes between cisplatin and carboplatin for the treatment of both limited-stage and extensive-stage small cell lung cancer (SCLC). The favorable toxicity profile of carboplatin and comparable overall survival support its use in clinical practice for both types of SCLC and allow for combination with novel treatment strategies in clinical trials.
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Dongsheng Yue, Shidong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu, Lanjun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Zhenfa Zhang, Bin Zhang, Changli Wang
Summary: This study provides updated results on the efficacy and safety of adjuvant erlotinib compared with chemotherapy in stage III EGFR+ non-small-cell lung cancer. The results show a clinically meaningful improvement in overall survival with adjuvant erlotinib.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Zaid Sirhan, Rawan Alojair, Anita Thyagarajan, Ravi P. Sahu
Summary: Lung cancer is a major malignancy globally, with NSCLC being the most common type. PTEN, a tumor suppressor gene, plays a critical role in regulating cancer growth and its dysfunction is associated with poor prognosis in lung cancer patients. PTEN has been explored as a promising target for anti-cancer agents, as it can interact with multiple signaling pathways to devise effective treatment options for NSCLC.
Article
Oncology
Yangyang Xu, Bing Wan, Suhua Zhu, Tianli Zhang, Jingyuan Xie, Hongbing Liu, Ping Zhan, Tangfeng Lv, Yong Song
Summary: This study found that adjuvant chemotherapy improves survival in stage IB NSCLC patients, especially in older patients, poorly differentiated tumors, 0-15 LNs examined, VPI, lobectomy, and no radiotherapy. Further prospective trials are needed to confirm these findings. Additionally, the nomogram provides relatively accurate prediction for the prognosis of resected stage IB NSCLC patients.
FRONTIERS IN ONCOLOGY
(2022)
